Qatar Investment Authority Joins $132M Series B Round for U.S. Biotech Firm Artbio

The funding supports Artbio, a biotech company developing advanced radiopharmaceutical treatments currently in the clinical stage.

This is the Qatar Investment Authority's first investment in the US-based company, Artbio.

Artbio is developing a new type of cancer treatment called alpha radioligand therapies (ARTs), designed to target and treat various forms of cancer.

Artbio said the Series B funding round was led by Sofinnova Investments and B Capital, along with a returning life sciences investment fund.

Additional support came from existing investors like F-Prime, Omega Funds, and Third Rock Ventures, as well as new investor Alexandria Venture Investments.

The company said the proceeds will be used to advance its development of ARTs.

QIA, managing $524 billion in assets, has been gradually increasing its investments in U.S. biotech companies.

In 2023, it led a $250 million funding round for BridgeBio Pharma, a Nasdaq-listed firm focused on genetic diseases and cancer treatments.

Read more- Singapore’s Hydroleap Raises $4.75M to Grow Eco-Friendly Water Tech in Asia